首页 > 市场调查报告书 > 製药

眼科药物

市场调查报告书

商品编码

1911686

干眼症市场规模、份额和成长分析（按产品、剂型、通路和地区划分）－2026-2033年产业预测

Dry Eye Syndrome Market Size, Share, and Growth Analysis, By Product (Over the Counter Artificial Tears & Lubricants, Prescription Drugs), By Dosage Form, By Distribution Channel, By Region - Industry Forecast 2026-2033

出版日期: 2026年01月01日 | 出版商:

SkyQuest | 英文 188 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，全球干眼症市场规模将达到 83.1 亿美元，到 2025 年将达到 89.6 亿美元，到 2033 年将达到 164.7 亿美元，预测期（2026-2033 年）的复合年增长率为 7.9%。

全球干眼症 (DES) 市场正经历显着成长，这主要得益于治疗方案从非处方润滑剂转向潜在发炎机制的处方药。处方药物技术的进步主要集中在缓解疾病疗法上，旨在解决睑板腺功能障碍、眼表发炎和泪膜不稳定等问题。干眼症盛行率的不断上升，尤其是在老年人和合併其他疾病的人群中，进一步推动了市场扩张。临床上显着的干眼症影响着超过 3,400 万美国，在欧洲和东亚的发病率也在上升，因此干眼症的治疗格局正在不断发展，以满足老龄化人口的需求。慢性疾病和体内化学物质的改变加剧了这种疾病的复杂性。

全球干眼症市场驱动因素

全球干眼症市场的主要驱动力是人口老化和干眼症状盛行率的上升。随着需要持续照护的老年人数量激增，处方药和非处方药的需求也相应增长。此外，长时间使用电子萤幕可能会导致润滑剂销售在短期内激增，并推动人们对治疗方案的长期关注。北美市场尤为突出，有望实现显着的财务成长。这种充满活力的市场环境必将为创新治疗方法和诊断服务在市场中永续发展提供机会。

全球干眼症市场限制因素

全球干眼症市场面临严峻挑战，原因在于相当一部分患者未被诊断和治疗。许多患者选择自行服用非处方药，而非寻求专业医疗咨询。这一趋势限制了製药公司开髮用于有效治疗干眼症的药物的收入成长潜力。因此，只有部分患者可能最终会转而使用处方药，这将进一步阻碍市场扩张，尤其是对于先进且昂贵的治疗方案。因此，只要人们对干眼症的认知和诊断率仍然较低，该市场就可能无法充分发挥其潜力。

全球干眼症市场趋势

全球干眼症市场正经历着一场意义深远的变革时期，治疗重点已从单纯缓解症状转向采用创新处方疗法解决根本病因。临床医师正逐渐抛弃传统的非处方药，转而选择针对发炎路径并增强泪膜稳定性的药物。这一趋势的驱动力源于新药的涌现以及旨在评估其长期疗效的临床试验的发展。此外，强化高价值的临床服务、制定专科处方集集以及积极的研发活动（包括胜肽、神经兴奋剂和缓释製剂等新型治疗方法）在重塑干眼症治疗模式方面发挥关键作用。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2025 年）
主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2023-2025年营收年比比较

主要企业简介

AbbVie Inc.（United States）
Bausch+Lomb（Canada）
Novartis AG（Switzerland）
Johnson & Johnson Services, Inc.（United States）
Santen Pharmaceutical Co., Ltd.（Japan）
Alcon Inc.（Switzerland）
Sun Pharmaceutical Industries Ltd.（India）
Otsuka Pharmaceutical Co., Ltd.（Japan）
Viatris Inc.（United States）
Kala Pharmaceuticals, Inc.（United States）
Novaliq GmbH（Germany）
AFT Pharmaceuticals（New Zealand）
Aldeyra Therapeutics（United States）
OASIS Medical（United States）
Akorn Operating Company LLC（United States）
Nicox SA（France）
Ocular Therapeutix, Inc.（United States）
Mitotech SA（Luxembourg）
Tarsus Pharmaceuticals, Inc.（United States）
Stuart Therapeutics（United States）

结论与建议

简介目录

Product Code: SQMIG35G2356

Global Dry Eye Syndrome Market size was valued at USD 8.31 Billion in 2024 and is poised to grow from USD 8.96 Billion in 2025 to USD 16.47 Billion by 2033, growing at a CAGR of 7.9% during the forecast period (2026-2033).

The global dry eye syndrome (DES) market is experiencing significant growth driven by a shift from over-the-counter lubricants to prescription therapies targeting underlying inflammatory mechanisms. Advancements in prescription drug technologies focus on disease-modifying treatments that address meibomian gland dysfunction, ocular surface inflammation, and tear-film instability. The escalating prevalence of dry eye disease, particularly among older populations and those with associated health conditions, further propels market expansion. With over 34 million Americans affected by clinically significant dry eye, and a rising incidence observed in Europe and East Asia, the landscape of dry eye treatment is evolving to meet the demands of an aging demographic. Long-standing diseases and chemical changes in the body contribute to the increasing complexity of this condition.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Dry Eye Syndrome market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Dry Eye Syndrome Market Segments Analysis

Global Dry Eye Syndrome Market is segmented by Product, Dosage Form, Distribution Channel and region. Based on Product, the market is segmented into Over the Counter (OTC) Artificial Tears & Lubricants, Prescription Drugs, Punctual Plugs, Nutraceuticals & Omega-3 Supplements and Autologous Serum & Blood-Derived Tear Substitutes. Based on Dosage Form, the market is segmented into Eye Drops and Ointments & Gels. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Independent Pharmacies & Drug Stores and Online Pharmacies & E-Commerce Portals. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Dry Eye Syndrome Market

The Global Dry Eye Syndrome market is primarily fueled by the increasing aging population alongside a growing prevalence of dry eye conditions. As the number of older individuals requiring ongoing care continues to escalate, there is a corresponding rise in the demand for both prescription and over-the-counter treatments. Additionally, prolonged screen time contributes to short-term spikes in lubricant sales and may foster long-term interest in therapeutic solutions. North America stands out as a key market, with significant financial growth anticipated. This dynamic landscape ensures that innovative treatments and diagnostic services will consistently have opportunities to thrive within the market.

Restraints in the Global Dry Eye Syndrome Market

The Global Dry Eye Syndrome market faces significant challenges due to a considerable portion of patients remaining undiagnosed and untreated. Many individuals opt for self-treatment using over-the-counter eye drops instead of seeking professional medical advice. This behavior limits the potential revenue growth for pharmaceutical companies developing treatments aimed at managing the condition effectively. As a result, there is a limited patient base transitioning to prescription medications, which can further hinder market expansion, especially for more advanced and costly treatment options. Consequently, the market may struggle to achieve its full potential as awareness and diagnosis of dry eye syndrome remain inadequate.

Market Trends of the Global Dry Eye Syndrome Market

The global dry eye syndrome market is undergoing a significant transformation as the focus shifts from merely alleviating symptoms to addressing the underlying disease processes through innovative prescription treatments. Clinicians are increasingly prioritizing medications that target inflammatory pathways and enhance tear film stability, moving away from traditional over-the-counter solutions. This trend is bolstered by the emergence of new medications and the initiation of clinical trials aimed at long-term efficacious outcomes. Enhanced offerings in high-value clinics, specialty formularies, and robust research and development efforts-including new classes of therapies such as peptides, neurostimulants, and sustained-release formulations-are playing a crucial role in reshaping treatment paradigms for dry eye syndrome.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Dry Eye Syndrome Market Size by Product & CAGR (2026-2033)

Market Overview
Over the Counter (OTC) Artificial Tears & Lubricants
Prescription Drugs
Punctual Plugs
Nutraceuticals & Omega-3 Supplements
Autologous Serum & Blood-Derived Tear Substitutes

Global Dry Eye Syndrome Market Size by Dosage Form & CAGR (2026-2033)

Market Overview
Eye Drops
Ointments & Gels

Global Dry Eye Syndrome Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Hospital Pharmacies
Independent Pharmacies & Drug Stores
Online Pharmacies & E-Commerce Portals

Global Dry Eye Syndrome Market Size & CAGR (2026-2033)

North America (Product, Dosage Form, Distribution Channel)
- US
- Canada
Europe (Product, Dosage Form, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product, Dosage Form, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product, Dosage Form, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Product, Dosage Form, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

AbbVie Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bausch + Lomb (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson Services, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Santen Pharmaceutical Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alcon Inc. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Otsuka Pharmaceutical Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Viatris Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kala Pharmaceuticals, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novaliq GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AFT Pharmaceuticals (New Zealand)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aldeyra Therapeutics (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
OASIS Medical (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Akorn Operating Company LLC (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Nicox S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ocular Therapeutix, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mitotech S.A. (Luxembourg)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tarsus Pharmaceuticals, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Stuart Therapeutics (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments